17,261 trials
Solid Organ Transplant Recipient (Liver, Kidney, Heart) · Rheumatologic Disorder · Human Immunodeficiency Virus (HIV)
Primary: Number of Episodes of Influenza and Influenza-Like-Illness Reported in High Dose and Standard Dose Vaccination Groups — 1; 1; 0; 0 episodes of illness
Small Cell Prostate Cancer · Neuroendocrine Prostate Cancer · Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
Primary: Response Rate, as Assessed by CT/MRI and Bone Scan, of Treatment With MLN8237 for Patients With Neuroendocrine Prostate Cancer — 18 participants
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Progression-free Survival > 6 Months — 18.8 percentage of participants
Alzheimer's Disease
Primary: Mean Change From Baseline in the 4-Item Agitation/Aggression Subscale of the Neuropsychiatric Inventory (NPI-4 A/A) at Week 12 — -5.4; -6.2 units on a scale
Tobacco Use Disorder
Primary: Abstinence — 10; 11 Participants
Iron Deficiency Anemia (IDA)
Primary: Maximum Serum Concentration (Cmax) — 157; 310 µg/mL
Asthma
Primary: Maximum Plasma Concentration (Cmax) of Mepolizumab for Part A — 12.8188; 16.3412; 10.1960 Microgram (ug) per mL
Calcinosis
Primary: Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Severity as Measured by a Difference in Physician Calcinosis Visual Analog Scales…
Leukemia, Mast-Cell · Mantle-cell Lymphoma
Primary: Chronic Graft-vs-Host Disease (cGvHD) — 20 percentage of participants
Prostate Cancer
Primary: Effects of Selenium and Finasteride and Their Combination on PSA Level — 1.9; 1.9; 2.0; 2.1 ng/mL — p=0.5137
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events
Adenoid Cystic Carcinoma
Primary: Overall Response Rate — 0; 3; 25; 4 Participants
Dry Eye
Primary: Mean Change From Baseline in Global Ocular Discomfort Score at Day 71 — -7.9; -3.6 units on a scale
Chronic Hepatitis C Infection
Primary: Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment — 95.5 percentage of participants
Salivary Gland Cancer
Primary: Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy — 0; 0; 18; 13 Participants